151. High protection of mice against Brucella abortus by oral immunization with recombinant probiotic Lactobacillus casei vector vaccine, expressing the outer membrane protein OMP19 of Brucella species.
- Author
-
Mohammadi E and Golchin M
- Subjects
- Administration, Oral, Animals, Antigens, Bacterial administration & dosage, Bacterial Outer Membrane Proteins administration & dosage, Brucella Vaccine administration & dosage, Brucella abortus, Brucellosis immunology, Cytokines immunology, Female, Humans, Immunity, Humoral, Immunity, Mucosal, Lipoproteins administration & dosage, Mice, Mice, Inbred BALB C, Probiotics administration & dosage, Vaccination methods, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Antibodies, Bacterial blood, Antigens, Bacterial immunology, Bacterial Outer Membrane Proteins immunology, Brucella Vaccine immunology, Brucellosis prevention & control, Lacticaseibacillus casei genetics, Lipoproteins immunology
- Abstract
Brucellosis is a zoonotic disease threatening the public health and hindering the trade of animals and their products, which has a negative impact on the economic development of a country. Vaccination is the most effective way to control brucellosis. The recombinant vector vaccines are promising candidates for immunization in humans and animals. In this study, the gene encoding OMP19 antigen was primarily amplified and cloned into an expression vector called pT1NX, and then transformed to L. casei cell via electroporation technique. The expression was confirmed using specific antibody against the recombinant protein via immunological screening tests such as western blot and immunofluorescence assay. Finally, recombinant L. casei was orally fed to mice and the results were further recorded, indicating that the mice group which received OMP19 through L. casei based vaccine represented a very good general and mucosal immune responses protective against challenges with virulent B. abortus 544 strain compared with negative control recipient groups. Therefore, the vaccine produced in this research plan can be a very good candidate for protection against brucellosis., Competing Interests: Declaration of Competing Interest We pronounce that we have no irreconcilable situation. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF